CompletedPhase 2

Safety Study for Beta Thalassemia Subjects on PTG-300

United States, Greece34 participantsStarted 2019-05-10

Plain-language summary

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

Who can participate

Age range12 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02. Exclusion Criteria: * Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD).

What they're measuring

Proportion of subjects with side effects and severity of side effects will be tabulated

Timeframe: Over two year Period after receiving PTG-300

Trial details

NCT IDNCT04054921

SponsorProtagonist Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-07-31

View on ClinicalTrials.gov More β-thalassemia trials